Literature DB >> 15896749

A descriptive study of small airway reticular basement membrane thickening in clinically stable lung transplant recipients.

Chris Ward1, Anthony De Soyza, Andrew J Fisher, Gail Pritchard, Ian Forrest, Paul Corris.   

Abstract

BACKGROUND: Chronic rejection functionally manifested by fixed airflow limitation, bronchiolitis obliterans syndrome (BOS), is a major problem for all lung allograft programs. The inclusion of a pre-BOS category (BOS(0 approximately p)) in the newly revised guidelines, recognizes the potential importance of early changes. We tested the hypothesis that small airway reticular basement membrane thickening exists even in clinically stable lung transplant recipients with some evidence of inflammation but who are BOS-free.
METHODS: A bronchoscopic study was performed on 30 clinically stable lung allograft recipients at >/=3 months post-allograft, who were BOS-free but with some evidence of airway inflammation indicated by a pathologic diagnosis of lymphocytic bronchiolitis or raised exhaled nitric oxide (NO). After baseline physiologic assessment, small airway reticular basement membrane (Rbm) thickening was quantified in transbronchial biopsy (TBB) using image analysis, with inflammation assessed by bronchoalveolar lavage (BAL) differential cell counts.
RESULTS: Twenty-one patients had technically satisfactory measurements of Rbm thickness. We detected small airway Rbm thickening when compared with published data for control lung diseases. There was no correlation between Rbm thickening and lung function (forced expiratory volume in 1 second [FEV(1)] best post-operatively and Rbm r = -0.10, not significant).
CONCLUSIONS: Our data suggest that airway remodeling can occur early in lung allografts and before development of airflow limitation and BOS. Longitudinal pathophysiologic studies are needed to elucidate potential relationships between airway inflammation, Rbm thickening and allograft failure. Airway biopsies would be of value in such studies.

Entities:  

Mesh:

Year:  2005        PMID: 15896749     DOI: 10.1016/j.healun.2004.02.018

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  5 in total

1.  Phenotype of airway epithelial cells suggests epithelial to mesenchymal cell transition in clinically stable lung transplant recipients.

Authors:  C Ward; I A Forrest; D M Murphy; G E Johnson; H Robertson; T E Cawston; A J Fisher; J H Dark; J L Lordan; J A Kirby; P A Corris
Journal:  Thorax       Date:  2005-06-21       Impact factor: 9.139

2.  Obliterative airway remodeling: molecular evidence for shared pathways in transplanted and native lungs.

Authors:  Danny Jonigk; Marlene Merk; Kais Hussein; Lavinia Maegel; Katharina Theophile; Michaela Muth; Ulrich Lehmann; Clemens L Bockmeyer; Michael Mengel; Jens Gottlieb; Tobias Welte; Axel Haverich; Heiko Golpon; Hans Kreipe; Florian Laenger
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

3.  Obliterative airway remodelling in transplanted and non-transplanted lungs.

Authors:  Danny Jonigk; Katharina Theophile; Kais Hussein; Oliver Bock; Ulrich Lehmann; Clemens L Bockmeyer; Jens Gottlieb; Stefan Fischer; Andre Simon; Tobias Welte; Lavinia Maegel; Hans Kreipe; Florian Laenger
Journal:  Virchows Arch       Date:  2010-07-15       Impact factor: 4.064

Review 4.  The Landscape of Digital Pathology in Transplantation: From the Beginning to the Virtual E-Slide.

Authors:  Ilaria Girolami; Anil Parwani; Valeria Barresi; Stefano Marletta; Serena Ammendola; Lavinia Stefanizzi; Luca Novelli; Arrigo Capitanio; Matteo Brunelli; Liron Pantanowitz; Albino Eccher
Journal:  J Pathol Inform       Date:  2019-07-01

5.  Beyond Bronchiolitis Obliterans: In-Depth Histopathologic Characterization of Bronchiolitis Obliterans Syndrome after Lung Transplantation.

Authors:  Arno Vanstapel; Stijn E Verleden; Eric K Verbeken; Peter Braubach; Tinne Goos; Laurens De Sadeleer; Janne Kaes; Bart M Vanaudenaerde; Danny Jonigk; Maximilian Ackermann; Laurens J Ceulemans; Dirk E Van Raemdonck; Arne P Neyrinck; Robin Vos; Geert M Verleden; Birgit Weynand
Journal:  J Clin Med       Date:  2021-12-25       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.